Page last updated: 2024-12-07

2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine: formed by Maillard recaction of bovine serum albumin with glucose; RN refers to (S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-(L-norleucin-6-yl)pyrraline : An N-substituted pyrraline formed via Maillard reaction of L-lysine with glucose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

pyrraline : A pyrrole having formyl and hydroxymethyl substituents at positions 2 and 5 respectively; useful as indicator of advanced stages of the Maillard reaction, which produces advanced glycation end-products (AGEs). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID122228
CHEBI ID59973
MeSH IDM0165674

Synonyms (28)

Synonym
pyrraline
2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine
2-fhmpn
74509-14-1
2-amino-6-(2-formyl-5-hydroxymethylpyrrol-1-yl)hexanoic acid
1-(l-norleucin-6-yl)pyrraline
epsilon-l-lysyl pyrraline
pyrraline-lysine
l-lysyl pyrraline
epsilon-l-lysylpyrraline
epsilon-lysylpyrraline
6-[2-formyl-5-(hydroxymethyl)-1h-pyrrol-1-yl]-l-norleucine
epsilon-pyrraline
epsilon-[2-formyl-5-(hydroxymethyl)pyrrole-1-yl]-l-norleucine
(s)-alpha-amino-2-formyl-5-(hydroxymethyl)-1h-pyrrole-1-hexanoic acid
CHEBI:59973 ,
(2s)-2-amino-6-[2-formyl-5-(hydroxymethyl)pyrrol-1-yl]hexanoic acid
1h-pyrrole-1-hexanoic acid, alpha-amino-2-formyl-5-(hydroxymethyl)-, (s)-
EPITOPE ID:136028
DTXSID30225507
6-(2-formyl-5-hydroxymethylpyrrol-1-yl)-l-norleucine
VTYFITADLSVOAS-NSHDSACASA-N
Q27126999
(s)-2-amino-6-(2-formyl-5-(hydroxymethyl)-1h-pyrrol-1-yl)hexanoic acid
EX-A3448
(2s)-2-amino-6-(2-formyl-5-hydroxymethylpyrrol-1-yl)hexanoic acid
(s)-2-amino-6-(2-formyl-5-(hydroxymethyl)-1h-pyrrol-1-yl)hexanoicacid
(2s)-2-amino-6-[2-formyl-5-(hydroxymethyl)-1h-pyrrol-1-yl]hexanoic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Peptide-enriched drinks (PEDs) are broadly consumed worldwide due to rapid rate of absorption and perceived health effects."( Determination of Free-Form and Peptide Bound Pyrraline in the Commercial Drinks Enriched with Different Protein Hydrolysates.
Li, B; Li, L; Liang, Z; Qi, H; Xu, Z; Zhang, X, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
L-lysine derivativeA proteinogenic amino acid derivative resulting from reaction of L-lysine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-lysine by a heteroatom.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
N-substituted pyrralinePyrraline in which the hydrogen attached to the nitrogen has been replaced by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.45)18.7374
1990's25 (36.23)18.2507
2000's17 (24.64)29.6817
2010's18 (26.09)24.3611
2020's8 (11.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.91 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index6.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.82%)5.53%
Reviews8 (11.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other61 (85.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]